US 12,383,602 B2
HLA-B57 open conformers
Osiris Marroquin Belaunzaran, Zurich (CH); Ulf Petrausch, Zurich (CH); and Christoph Renner, Zurich (CH)
Assigned to UNIVERSITAT ZURICH, Zurich (CH); and UNIVERSITAT BASEL, Basel (CH)
Filed by UNIVERSITAT ZURICH, Zurich (CH); and UNIVERSITAT BASEL, Basel (CH)
Filed on Jun. 26, 2022, as Appl. No. 17/849,643.
Application 17/849,643 is a continuation of application No. 16/083,508, granted, now 11,369,660, previously published as PCT/EP2017/055373, filed on Mar. 7, 2017.
Claims priority of application No. 16159099 (EP), filed on Mar. 8, 2016.
Prior Publication US 2022/0339250 A1, Oct. 27, 2022
Int. Cl. A61K 38/17 (2006.01); A61P 35/00 (2006.01); A61P 37/02 (2006.01); C07K 14/74 (2006.01)
CPC A61K 38/1774 (2013.01) [A61P 35/00 (2018.01); A61P 37/02 (2018.01); C07K 14/70539 (2013.01); C07K 2319/30 (2013.01)] 6 Claims
 
1. An isolated Human Leukocyte Antigen-B57 (HLA-B57) fusion protein, comprising:
a first and a second monomer, and wherein each monomer independently of the other monomer comprises:
a HLA-B57 heavy chain,
an Fc (crystallizable fragment) domain polypeptide sequence, and
optionally, an amino acid linker joining the HLA-B57 heavy chain and the Fc domain,
wherein the HLA-B57 chain comprises ≥95% sequence identity to SEQ ID NO: 7.